James Spicer, FRCP, PhD, MB, BS
James Spicer is a Reader in the Cancer Studies Division of King’s College London, and Honorary Consultant in Medical Oncology at Guy’s and St. Thomas’ Hospitals. He trained at major London teaching hospitals, has a Ph.D. in cancer biology from the Institute of Cancer Research in London, and a degree in biochemistry from the University of Oxford. Dr Spicer specialises in the treatment of thoracic malignancies especially lung cancer. His research interests include early phase trials, and novel therapies for lung cancer and other thoracic malignancies. He has established a phase I programme in solid tumour oncology at Guy’s Hospital, and is lead for thoracic medical oncology.
He co-leads the King’s Experimental Cancer Medicine Centre, and a member of the Board of the King’s Health Partners Clinical Trials Office. He also conducts translational research on novel immunotherapies, pharmacogenetics and molecular diagnostics. He is a member of the British Thoracic Oncology Group steering committee, and sits on CRUK’s New Agents committee and other national research funding panels. He is the author of more than 70 peer-reviewed publications.
Gonçalo Bernardes, D.Phil.
Professor Bernardes has a D.Phil. degree from the University of Oxford. He was awarded a Marie-Curie Fellowship to perform postdoctoral studies with Prof. Peter H. Seeberger in Antibody Drug Conjugation. From September 2010 until October 2012, Gonçalo was an EMBO Fellow in the group of Prof. Dario Neri at the ETH Zürich where he developed novel vascular targeting antibody-drug conjugates (ADCs) for cancer therapy. Since October 2012, Gonçalo is at the Deparment of Chemistry, University of Cambridge, UK where he holds a prestigious Royal Society University Research Fellowship.
In addition, he is also the Director of the Chemical Biology and Pharmaceutical Biotechnology Unit at the Instituto de Medicina Molecular (UMM) in Lisbon. His research has resulted in more than 30 peer review publications, 4 patents and he has been invited to present his research in more than 50 conferences/institutes worldwide. Gonçalo has recently been awarded the EFMC Prize for Young Medicinal Chemist in Academia and has been distinguished by the Ministry of Health (MH) of Portugal for relevant services to Public Health and Medicine.
Nuno Sousa, M.D., Ph.D.
Nuno is a Full Professor at the School of Health Science. He is the Director of the Medical Degree at University of Minho. He serves at several medical education and medical assessment advisory boards, including the National Board of Medical Examiners (NBME) in the US and the European Board of Medical Assessors (EBMA).Nuno is a Neuro-radiologist and presently, he is the Director of the Clinical Academic Center at Hospital de Braga, where he coordinates and is involved in several national and international research projects. His main research interests are focused in the establishment of functional and structural correlations mediated by stress and aging and its implications in cognition and in neuropsychiatric disorders.
Nuno is the coordinator of the Neuroscience Research Domain at ICVS/University of Minho, and has published more than 150 peer-reviewed research articles. In addition to his academic and research merits, Nuno Sousa serves on several science policy and advisory board positions, and as an Ad hoc reviewer for various neuroscience journal and international funding organizations. He is Editor-in-Chief of Frontiers in Behavioral Neuroscience and Member of the Editorial Board of Molecular Neurodegeneration. Since May 2011 Nuno Sousa is also the President of the Portuguese Society for Neuroscience. He has received various international prizes, such as the Grunenthal Prize in both 2003 and 2007, and the Janssen Neuroscience Prize 2012, amongst others.
Claudia De Lorenzo, Ph.D.
Claudia De Lorenzo is an Associate Professor since 2010 at the Department of Molecular Medicine and Medical Biotechnology, University "Federico II", and a group leader at CEINGE, Napoli, Italy. After her degree in Biological Sciences and a Ph.D. in Biochemistry and Molecular Biology, she has been working as a visiting fellow, funded by CIB (Consorzio Interuniversitario Biotecnologie), at the Department of Immunology, Imperial College School of Medicine, and the Hammersmith Hospital, London, U.K.
In June 2002 she was appointed full time researcher at the University of Napoli "Federico II" where she has directed her interests towards anti-cancer immunotherapy. Her research group has world-wide recognition in the discovery and characterization of novel human immunoagents and associated translational biology aspects. Claudia is a co-author of several patents. She has been awarded a prize as young researcher by Italian Foundation for Cancer research "Guido Berlucchi" in 2005. More recently she has directed her research activity at investigating the molecular basis of the different cardiotoxic effects among the ErbB2 inhibitors by testing their effects in vitro on rat and human cardiomyocytes and in vivo on a mouse model. Her present research interest is focused in the development of novel human immunoconjugates and immune-modulators and their use in immune-oncology approaches as well as novel antibody discovery activities using phage display technologies. These novel antibodies are specific for new tumour associated antigens and other targets useful for diagnosis and/or therapy of different diseases.